An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors

An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors

Abstract Epidermal growth factor receptor (EGFR) mutations identify patients with lung cancer who derive benefit from kinase inhibitors. However, most patients eventually develop resistance, primarily due to the T790M second‐site mutation. Irreversible inhibitors (e.g., osimertinib/AZD9291) inhibit...

Full description

Bibliographic Details
Main Authors: Maicol Mancini, Hilah Gal, Nadège Gaborit, Luigi Mazzeo, Donatella Romaniello, Tomer Meir Salame, Moshit Lindzen, Georg Mahlknecht, Yehoshua Enuka, Dominick GA Burton, Lee Roth, Ashish Noronha, Ilaria Marrocco, Dan Adreka, Raya Eilam Altstadter, Emilie Bousquet, Julian Downward, Antonio Maraver, Valery Krizhanovsky, Yosef Yarden
Format: Article
Language:English
Published: Springer Nature 2017-12-01
Series:EMBO Molecular Medicine
Subjects:
antibody therapy
apoptosis
kinase inhibitor
NSCLC
T790M
Online Access:https://doi.org/10.15252/emmm.201708076

Internet

https://doi.org/10.15252/emmm.201708076

Similar Items